This phase is a double-blind, placebo controlled efficacy and safety trial in adults following hip or knee replacement surgery.
The third study will test the new product on 400 patients, randomized 3:1, and will be conducted at 45 academic and community hospitals in the country.
The ARX-01 system is designed to address the limitations of current PCA with morphine by offering a high therapeutic index opioid with low instance of drug-related side effects.
More Articles on Anesthesia:
Anesthesiology: Blood Clotting Algorithms Can Reduce Transfusion Requirements, Cut Hospital Costs
Endo Health Solutions Reports Above Expectations $785M Revenue Increase
New Anesthetic Agents Could Outperform Current Drugs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
